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Summary p53 alterations at the DNA, mRNA and protein levels were studied in tumour metastases sampled
from 30 patients with malignant melanoma. Paraffin-embedded sections from these and an additional 12
patients were examined for the presence of p53 protein. TP53 gene aberrations were found in 7 of 30 (23%) of
the patients, six of which showed loss of heterozygosity (LOH). Point mutations were detected in only two
cases, one of which had LOH whereas the other was non-informative. Increased levels of p53 mRNA were
present in only one tumour with, but in six cases without, detectable DNA abnormalities. Four of the latter
and six tumours with normal transcript levels had immunohistochemically detectable levels of p53 protein. In
25 cases in which corresponding primary and metastatic lesions could be compared, closely similar
immunoreactivity patterns were observed. Increased expression of the MDM2 gene was found in only one
tumour in parallel with overexpression of p53. Altogether, the data indicate that inactivation of the p53
regulatory pathway is not of major significance in the tumorigenesis of malignant melanoma. However, a
significant association was found between p53 immunoreactivity and the relapse-free period in patients with
superficial spreading melanoma. That increased protein expression was predominantly found in tumours
without DNA alterations might suggest a role for the wild-type p53 protein in restricting malignant cell
proliferation in these cases.
The TP53 gene, which is localised to chromosome fragment
l7pl3 (Isobe et al., 1986), appears to be one of the genes
most commonly altered in human cancer cells (Vogelstein,
1990; Caamano et al., 1992; Andreassen et al., 1993). The
gene encodes a nuclear phosphoprotein that has been sug-
gested to function as a control factor in the repair of
damaged DNA (Kastan et al., 1991) and in cell growth
control by acting as a transcriptional regulator (Levine et al.,
1991).
Loss of protein function may occur when a mutation is
accompanied by a deletion in the remaining allele (Nigro et
al., 1989). Furthermore, it has been suggested that mutated
p53 and other proteins may bind and inactivate wild-type
p53 (Kraiss et al., 1988; Lehman et al., 1991). Thus, the
mdm2 (murine double minute 2) gene product has been
shown to interact with both wild-type and mutated p53,
thereby inhibiting p53-mediated transactivation in a dose-
dependent manner (Momand et al., 1992). Moreover, MDM2
amplification and overexpression have been shown in a sub-
stantial number of sarcomas and glioblastomas with normal
TP53 (Oliner et al., 1992; Ladanyi et al., 1993; Reifenberger
et al., 1993; Fl0renes et al., submitted), suggesting that alter-
ations involving these two genes are alternative mechanisms
for escaping p53-regulated growth control (Oliner et al.,
1992).
Wild-type p53 is known to have a very short half-life (Iggo
et al., 1990), whereas most TP53 mutations result in a
stabilised protein. Recently, however, evidence has been
obtained suggesting that under some circumstances wild-type
p53 may also accumulate in cells, probably by complex for-
mation with other proteins or by oligomerisation (Lehman et
al., 1991). In accordance with this, accumulation ofwild-type
p53 has been observed in proliferating, mitogen-stimulated
lymphocytes (Rivas et al., 1992) and in the basal layer of
human skin in response to mild UV irradiation (Hall et al.,
1993).
Relatively few reports on p53 aberrations in melanoma
have been published. In the Li-Fraumeni syndrome, in
which melanoma represents one of the tumour forms,
inherited TP53 mutations seem to be present in around 70%
of the cases examined (S. Friend, personal communication).
Among nine human melanoma cell lines, a point mutation
within the TP53 gene was found in only one (Volkenandt et
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al., 1991). In contrast, p53 protein, as detected by
immunohistochemistry, has been reported to be present in a
very high percentage (70-98%) of melanomas (Stretch et al.,
1991; Akslen & Morkve, 1992).
The aim of the present work was to study a panel of
malignant melanomas of different histological subtypes and
at different stages of disease progression for TP53 allele
deletions, gene mutation and the tumour levels of p53
mRNA and protein. Attempts were also made to relate the
p53 status to the mRNA expression of mdm2 and to known
clinical parameters for melanoma progression.
Materials and methods
Specimens
Fresh tumour tissue from metastatic lesions and peripheral
blood cells were sampled from 30 patients with malignant
melanoma. Upon surgical removal the tissue was frozen
immediately at - 135C. Formalin-fixed, paraffin-embedded
sections of melanoma metastases were obtained from the
same 30 patients and from an additional 12 patients.
Archival paraffin-embedded tissue from the primary tumour
was obtained in 25 cases, and in seven cases material from
different metastases, appearing at various stages of the
disease, was available for examination. Nineteen of the 42
melanomas were classified as superficial, 13 as nodular, six
belonged to other histological subgroups, and the primary
tumour was unknown in four cases.
Southern blot analysis
Genomic DNA from melanoma tissues and peripheral blood
cells was isolated by standard methods (Maniatis et al.,
1982). Aliquots (10pg) of DNA were digested with an appro-
priate restriction enzyme, separated on 0.8% agarose gels
and transferred onto Hybond-N+ membranes (Amersham,
Amersham, UK), according to the manufacturer's manual.
After baking for 2 h at 80°C and subsequent UV cross-
linking, the blots were hybridised with DNA probes labelled
with 32P by the random primer technique (Feinberg &
Vogelstein, 1983). The hybridisation was carried out in 0.5 M
sodium phosphate pH 7.2, 7% SDS and 1 mM sodium
EDTA at 65°C for 16 h as described by Church and Gilbert
(1984). After hybridisation, the membranes were washed
three times for 20 min in 40 mM sodium phosphate (pH 7.2)
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and 1% SDS. For multiple hybridisations, the bound probe
was removed by incubating the filters twice for 5 min in
0.1 x standard saline citrate (2 x SSE = 3.0 M sodium chloride,
0.3M sodium citrate, pH 7.0) and 0.1% SDS at 95-100°C.
Probes and restriction enzymes
To detect allelic deletions within the area of the TP53 gene
on chromosome fragment 17p, the following probes and
restriction enzymes were used: 144-D6 (17pl3.3), MspI,
(Kondeleon et al., 1987); YNZ22 (17pl3.3), TaqI,
(Nakamura et al., 1988); pBHp53 (17pl3.1), BamHI,
(H0yheim et al., 1989) and pHF12-2 (17pl2.2), MspI (Naylor
et al., 1984). An MDM2 cDNA probe (Oliner et al., 1992),
kindly provided by B. Vogelstein, The Johns Hopkins
University School of Medicine, Baltimore, MD, USA, and
D. George, University of Pennsylvania, Philadelphia, PA,
USA, was used to detect MDM2 mRNA. A human p53
40-mer oligonucleotide probe (localised near the 5' end of the
gene) was provided by Oncogene Science (Uniondale, NY,
USA). A human-specific 18S rRNA oligonucleotide probe
complementary to nucleotides 287-305 was used for cali-
brating the amounts of RNA.
Polymerase chain reaction - restrictionfragment length
polymorphism (PCR-RFLP)
To detect restriction enzyme polymorphisms within exon 4
(codon 72) of the TP53 gene, genomic DNA from the
tumours and peripheral blood cells was amplified by PCR
using two 23-oligomer primers as described by Ara et al.
(1990). The PCR products were digested with the restriction
enzyme BstUI, separated by polyacrylamide gel elect-
rophoresis and visualised by ethidium bromide staining of
the gels.
The exon 6 to intron 6 region of TP53, which contains a
MspI polymorphic site, was amplified using one 20- and one
24-oligomer primer as previously described (McDaniel et al.,
1991; Andreassen et al., 1993).
Mutation analysis ofthe TP53 gene
DNA from the tumours was analysed for possible TP53
mutations using the CDGE method (Hovig et al., 1991). The
screening was performed using PCR primers amplifying
codons 128-153 (fragment A) and 155-185 (fragment B) of
exon 5, codons 237-253 (fragment C) of exon 7 and codons
265-301 (fragment D) of exon 8 (B0rresen et al., 1991).
Samples that showed aberrantly migrating bands, indicating
mutations, were submitted to PCR performed with one
biotinylated primer. The biotinylated PCR products were
subsequently sequenced directly using the standard dideoxy
method and Dynabeads M280-Stretavidin (Dynal, Norway)
as solid support (Hultman et al., 1989).
Northern blot analysis
Total RNA was isolated from the tumours by the
guanidinium thiocyanate-phenol-chloroform extraction
method described by Chomczynski and Sacchi (1987) or the
guanidinium thiocyanate-caesium chloride method described
in Maniatis et al. (1982). Samples of 5 sg of total RNA were
resolved by electrophoresis on 1% agarose-formaldehyde
gels (Maniatis et al., 1982), blotted in 10 x standard saline
citrate onto Hybond-N+ membranes (Amersham), baked,
stripped and hybridised to a kinase-labelled human p53 40-
mer oligonucleotide probe as recommended by the manufac-
turer (Oncogene Science), and to a kinase-labelled (Maniatis
et al., 1982) oligonucleotide specific for human 18S rRNA to
correct for unequal RNA loading.
Immunohistochemistry
Sections from formalin-fixed, paraffin-embedded tissues were
immunostained using the avidin-biotin-peroxidase complex
(ABC) method described by Hsu et al. (1981). Briefly, the
sections were incubated for 18-22h at 4°C with the poly-
clonal p53 antiserum NCL-CM1 (Novocastra Laboratories),
diluted 1:500, or with the monoclonal antibody PAb 1801
(Oncogene Science), diluted 1:100 (1 jig IgGl ml 1), followed
by sequential incubations with biotin-labelled secondary
antibody and avidin-biotin-peroxidase complex. The reac-
tion was finally developed using diaminobenzidine as
chromogen. All series included positive controls. Negative
controls included substitution of polyclonal primary
antiserum with normal rabbit serum diluted 1:300, whereas
negative controls for the monoclonal antibody were per-
formed using mouse myeloma protein of the same subclass
and concentration as the monoclonal antibody. Four semi-
quantitative classes were used to describe the number of
positively stained tumour cells: (-) none, (+) <5%, (+ +)
5-50%, (+++) >50%.
Clinicalparameters
The following clinical parameters for disease progression
were assessed: localisation of the primary tumour, depth of
growth in millimetres, and relapse-free period (months) from
diagnosis of the primary tumour to development of distant
metastasis.
Results
RFLP studies
DNA from 30 matched pairs of melanoma metastases and
peripheral blood cells was studied for LOH on chromosome
fragment 17p. As summarised in Figure 1, the tumours of
seven patients (23%) had lost one or more alleles of the
examined loci. In one additional case (No. 9) a rearranged
(abnormal) band pattern was found with the YNZ22
probe.
Using the pBHp53 probe, which is located close to the
TP53 locus, three (nos. 1, 3 and 5) of 10 (30%) informative
cases showed LOH, and in one additional case (no. 2) a
rearranged band pattern plus an extra restriction fragment
was observed. In the 29 cases in which PCR-RFLP analyis
of codon 72 (exon 4) and of the exon 6 to intron 6 region of
the TP53 gene could be performed, LOH within codon 72
was found in 3 of 13 (23%) informative cases (nos. 2, 4 and
6). In addition, the loss of codon 72 on both TP53 alleles
was detected in two cases (nos. 1 and 3). In these two
tumours, the deletions within codon 72 and at the pBHpS3
locus were accompanied by LOH at two polymorphic loci
distal to TP53 (144-D6 and YNZ22). In case 8, LOH was
found with the YNZ22 probe, whereas both codon 72 and
pBHpS3 were non-informative. In only one patient (no. 5)
LOH centromeric (D17S1) to TP53 was found, together with
the loss detected with the pBHp53 probe. None of the infor-
mative cases showed LOH within the exon 6 to intron 6
region (not shown).
Mutation analysis
In an attempt to detect point mutations within TP53, we
performed CDGE analysis covering the four 'hotspots' in
exons 5, 7 and 8. Aberrantly migrating bands were found in
only two (7%) of the melanoma metastases (Figure 1). In
one of these (no. 6) a mutation within codons 155-185 (exon
5) was present together with LOH involving codon 72 (exon
4). In the other case (no. 7) the mutation was localised to
codon 275 of exon 8, whereas the RFLP data from this
tumour were not informative. Interestingly, upon sequencing,
a TGT-*TGG transversion involving a change from cysteine
to tryptophan was detected (Figure 2a), a mutation which
has not previously been described.p53 ABERRATIONS IN MALIGNANT MELANOMA 255
Patient ,LOH m Metastasis Primary tumour
I 144-D6 YNZ22 Codon 72 pBHp53 D17S1 ImRNA Protein Protein Subtype
1 0 0 - * 0 N - - Nodular
2 0 0 0 Abn 0 - - - Desmopl.
3 0 0 - 0 0 N - - Nodular
4 2'1, 0 0 ° 0 ++ - - Nodular
5 2 0 2' * 0 N + - Superi.
6 ND ND * ND ND e - - - Lentigo
7 0 0 e2 ND 0 D ND + + Supert.
8 0 0 -a z ND + - ND Nodular
9 0 Abn 0 2' - ND - ND Superf.
10 0 0 -a -o ND +++ ++ ++ Superf.
11 0 0 ND -o ND +++ ++ ++ Superf.
12 0 -o 2' -a ++ ++ +++ Superf.
13 ND ND ' 2 2 ++ ++ ND Supert.
14 -a 0 0 ND ++ - ND Superf.
15 2e 0 0 2 N+Abn + ND Nodular
16 0 0 2 2' N ++ ++ Superi.
17 0 0 0 2' 2 N ++ - Supert.
18 0 0 2' 2 4' N + + Superf.
19 -a 2' 0 2' ND N + - Nodular
20 0 0 -a 2' ND N - + Nodular
21 ND 0 0 ND ND N - - Superi.
22 0 0 2' -o 0 N ND - Superf.
23 0 -a 0 0 0 N - - Superi.
24 0 0 0 0 ND ND - ND Nodular
25 0 0 2' 0 0 ND - ND Superf.
26 0 0 0 0 2' N - ND ND
27 0 0 0 0 2 N - ND Nodular
28 -a 2' -a 2 2' ND - - Nodular
29 0 0 2' 2' 2' N - ND Lentigo
30 0 0 0 2' ND N - ND Superf.
Figure 1 Schematic illustration of LOH on chromosome segment 17p, of TP53 mutations, and of mRNA and protein levels in
tumour samples obtained from 30 patients with malignant melanoma. LOH: 0, heterozygous; 0, loss of heterozygosity; 0;
non-informative; Abn, altered restriction fragment pattern. mRNA: N, normal transcript level; + to + + +, increasing transcrip-
tion level; Abn, truncated transcript. Protein, expression level quantitated as in Materials and methods. ND, not determined.
M, mutation; B, fragment B (codons 155-185); D, fragment D (codons 265-301).
TP53 abnormalities,p53 mRNA andprotein expression
The summary (Figure 1) of the results in the 30 patients for
whom TP53 abnormalities and mRNA and protein expres-
sion could be studied in parallel permits evaluation of possi-
ble relationships between data obtained by the different
methods. It can be seen that only one (no. 5) of the six
patients with LOH involving the TP53 gene had immuno-
histochemically detectable levels of p53 protein, whereas the
p53 mRNA level was normal. In addition, one (no. 7) of the
two cases with mutated TP53 stained positive for protein,
both in the metastasis (Figure 2b) and in the primary
tumour. Of the cases without detectable LOH or mutations,
four tumours (nos. 10, 11, 12 and 13) had elevated levels of
p53 mRNA accompanied by relatively high amounts of pro-
tein in the primary tumours and in the metastases
examined.
In two cases (nos. 4 and 14) high p53 mRNA levels were
found in tumours that lacked protein expression. Moreover,
in the two cases (nos. 1 and 3) with homozygous deletion of
codon 72, the mRNA transcript seemed normal, although the
tumours were immunohistochemically negative. This appar-
ent discrepancy is probably due to contamination of the
preparation with cells with wild-type p53. Finally, among all
tumours with normal transcript levels, six expressed protein,
whereas nine stained negatively.
Immunohistochemical staining ofmetastatic andprimary
melanomas
Tissues from distant metastases of all the 42 patients were
examined for expression of p53 protein. In 16 cases (38%),
positive immunostaining with the polyclonal NCL-CM 1
antiserum was observed. In most of these, 5-50% of the
tumour cells were immunoreactive, whereas the other positive
specimens were characterised by only rare p53-positive cells
(= <5%). The staining was in all cases exclusively localised
to the cell nucleus.
In five of the p53 protein-positive cases, tissue from multi-
ple metastases was available. In four of these, the same
degree of positive immunostaining was observed in all sam-
ples (not shown). From the fifth patient, four metastases had
been sampled at different times of disease progression. In the
two earliest manifested metastases the tumour cells stained
negative, but in one of the samples, obtained from a sub-
cutaneous metastasis in the front of the head, immunoreac-
tivity was observed in some of the normal cells surrounding
the tumour. However, this patient showed signs of sunlight-
related degeneration of the dermis. In the two metastases
that had developed at a later stage, between 5 and 50% of
the tumour cells were stained.
In 25 cases in which p53 protein expression had been
studied in metastatic lesions, formalin-fixed tissues from the256 V.A. FL0RENES et al.
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Figure 2 TP53 mutation and p53 protein expression observed in
the metastasis of patient No. 7. a, Direct sequencing of exon 8
performed as described in Materials and methods. The point
mutation within codon 275 (TGT->TGG) is indicated with an
arrow. b, p53 protein in the same patient as detected by
immunohistochemical staining using the NCL-CM 1 antiserum
was performed as described in Materials and methods.
corresponding primary tumour were also available for
immunohistochemical analysis. Positive staining was
observed in nine (36%) of the primary tumours. In six of the
nine cases the number of cells expressing p53 protein was the
same in the samples from the primary tumours and the
corresponding metastases. In the three other cases in which
tumour cells in the primary tumours expressed p53 protein,
no staining was observed in the several metastases
studied.
mRNA expression ofMDM2 in relation to p53 status
In an attempt to examine whether the observed accumulation
of p53 protein in cases without detectable TP53 gene abnor-
malities might be due to alterations involving MDM2, the 30
tumour metastases were analysed for expression of MDM2
mRNA. It was found that the transcript was expressed at
detectable levels in only one of the cases (no. 13, data not
shown). This tumour had no aberration of TP53 DNA, but
showed increased mRNA expression and immunohisto-
chemically detectable p53 protein. However it should be
noted that none of the other tumours with similar p53
findings expressed detectable levels of MDM2 mRNA.
p53 abnormalities and clinicalparametersfor melanoma
progression
When p53 protein levels in the primary tumours were cor-
related with disease progression parameters, such as his-
tological subtype, thickness and localisation of the primary
tumour and the time from biopsy of the primary to develop-
ment of distant metastases, the following patterns could be
seen: 11 of 19 (58%) of the superficially growing melanomas
showed p53 protein immunoreactivity, whereas only 3 of 13
(23%) of those belonging to the nodular subtype were
stained (Table I). In the limited number of cases studied, the
patients with superficial tumours that expressed p53 protein
had a significantly longer relapse-free period (mean 47
months) compared with those with no detectable amounts of
p53 protein (mean 20 months) (P = 0.03; Mann-Whitney
two-tailed test). The observed difference in disease progres-
sion was independent of the thickness of the primary tumour,
which was about the same in both groups. No relationship
was found between p53 protein expression and localisation of
the primary tumours (not shown), or between TP53 gene
alterations and any of the evaluated clinical parameters.
Discussion
Genetic abnormalities involving chromosomes 1, 6, 7 and 9
are frequent (44-83%) in malignant melanoma, whereas
chromosome 17 alterations seem to be relatively rare. Thus,
in the material reviewed by Fountain et al. (1990), only 22%
of the melanomas were found to harbour chromosome 17
aberrations, as detected by cytogenetic analysis. Nevertheless,
it has been suggested that the TP53 gene located on
chromosome 17 may be involved in melanoma development,
as a high fraction of tumour samples studied by immunohis-
tochemistry stained positively for p53 protein, indicating p53
aberrations (Stretch et al., 1991; Akslen &M0rkve, 1992). In
an attempt to elucidate this possibility further, we analysed
surgically removed metastatic tumours from patients with
malignant melanoma for LOH on chromosome arm 17p, for
TP53 point mutations and p53 mRNA levels. In addition,
the metastases and the corresponding primary tumours were
studied by immunocytochemistry for expression of the pro-
tein.
TP53 gene aberrations were observed in the metastases of
7 of 30 (23%) melanoma patients. Six tumours showed LOH,
whereas gene mutations were detected by CDGE analysis in
only two cases. One of these, which was non-informative for
the TP53 loci, had a mutation at codon 275 of exon 8, as
identified by sequencing. The other contained a mutation in
exon 5 of the gene, which unfortunately could not be
confirmed upon sequencing because of the limited sensitivity
of the direct squencing method (Condie et al., 1993). That a
mutation was detected in only one of six cases with LOH is
in accordance with previous reports suggesting that muta-
tions and LOH may represent independent events (Osborne
et al., 1991; Coles et al., 1992; Toguchida et al., 1992). The
possibility exists that the frequency of gene mutations in our
material may be underestimated, as the screening was
restricted to exons 5, 7 and 8, but since more than 85% of all
known TP53 mutations have been localised to exon 5-8 this
possibility does not seem likely (Nigro et al., 1989; Hollstein
et al., 1991). Tobal et al. (1992) recently suggested on the
basis of findings in choroidal melanomas that abnormalities
of TP53 may be important in melanoma development. How-
ever, our results, together with data obtained on a panel of
30 cases of primary and metastatic melanoma, in which no
point mutations were detected (P.A. Albino, personal com-
munication), indicate that TP53 mutations are not of major
significance in the tumorigenesis of malignant cutaneous
melanomas.
Previously, Akslen and M0rkve (1992) and Stretch et al.
(1991) reported p53 protein immunoreactivity in 97% and
85% of malignant melanomas respectively. In contrast to
their findings, only 38% of the 42 metastatic lesions and 36%
of the primary melanomas in the present study expressedp53 ABERRATIONS IN MALIGNANT MELANOMA 257
Table I Relationship between p53 protein expression in melanomasa and clinical parameters of
malignancy
Tumour No. of Depth ofprimary Relapse-free
subtype Immunohistochemistry patients tumour (mm) period (months)
Superficial Positive 11 2.30 47 = b
Negative 8 2.28 20 P 0,03
Nodular Positive 3 1.80 47
Negative 10 2.30 44NS
Otherc Positive 0 - -
Negative 6 2.61 14
Unknownd Positive 2 ND ND
Negative 2 ND ND
aCases with either positive or negative staining in both the primary tumour and the corresponding
metastasis. bMann-Whitney two-tailed test. cFour cases of lentigo, one anaplastic and one desmoplastic
malignant melanoma. dCases where the primary tumour was unknown. NS, not significant; ND, not
determined.
detectable amounts of p53 protein. This discrepancy could
not be explained by the use of different antibodies, as was
demonstrated when some of the tumours in our material
were examined in parallel (not shown) with the polyclonal
CM1 antiserum and the monoclonal antibody PAb 1801 used
by Akslen and M0rkve (1992). It is noteworthy that Akslen
(1993) has recently emphasised that positive staining may in
some cases be artificial. The observed heterogeneity in stain-
ing pattern within each tumour found here seems to represent
a common finding in different types of cancer (Stretch et al.,
1991; Akslen & M0rkve, 1992; Holm et al., 1992; Pignatelli
et al., 1992; Thor et al., 1992). It has been suggested that this
may result from cell cycle variations (Bartek et al., 1990) or
that different mutations and wild-type p53 may exist within
the same tumour (Wynford-Thomas, 1992).
In accordance with findings obtained in squamous cell
carcinoma (Dolcetti et al., 1992) and in breast cancer
(Davidoff et al., 1991), we observed similar levels of protein
accumulation in pairs of primary melanomas and the corre-
sponding metastases. Recently, Sidransky et al. (1992)
reported a clonal selection during the progression of primary
brain tumours of cells containing mutated TP53. Our data
do not support this hypothesis in melanoma because the
percentage of stained cells in the one tumour with mutation
(no. 7) was the same in the primary and the metastatic lesion
where this could be compared. Moreover, in disagreement
with the results of Lassam et al. (1993), we observed almost
identical staining patterns in primaries and metastases with-
out detectable mutations, and also in different metastases
obtained from the same patients at different points of
time.
It has recently been shown that p53 protein expression
may be induced in the basal layer of human skin after mild
exposure to UV radiation (Hall et al., 1993). This finding
makes p53 expression studies in malignant melanomas parti-
cularly interesting in the light of the association between
increased incidence of melanomas and increased exposure to
UV light (Koh, 1991). It is not inconceivable that the
elevated levels of p53 protein we found in normal cells
surrounding two tumours may have been induced in response
to UV radiation, reflecting the putative role of p53 in repair-
ing damaged DNA (Kastan et al., 1991) and in suppressing
cell proliferation (Fields & Jang, 1990).
The p53 mRNA levels were increased in six tumours that
had no detectable abnormalities of the TP53 gene, and four
of these cases also showed relatively strong immunostaining
for p53 protein (5-50% of stained cells). In addition, six
tumours with normal mRNA levels contained areas with
stained cells. These data might suggest that p53 can be
involved in determining the malignant potential of the
tumours in the absence of detectable DNA aberrations. The
possibility that the increased protein levels may represent
wild-type and not mutated protein is supported by recent
reports suggesting that wild-type protein may be stabilised by
complex formation with other proteins or by oligomerisation
(Lehman et al., 1991).
By its ability to complex with p53, overexpression ofmdm2
has been suggested to provide an alternative pathway of
inactivating p53 in cases with no abnormalities of the TP53
gene (Momand et al., 1992; Oliner et al., 1992; Ladanyi et
al., 1993; Reifenberger et al., 1993). Furthermore, an interac-
tion between the two proteins at the transcriptional level has
recently been suggested (Barak et al., 1993; Fl0renes et al.,
submitted). Since overexpression of MDM2 mRNA was
found here in only one case, in parallel with increased expres-
sion of p53 mRNA and protein, it is unlikely that mdm2 is of
importance in the development and progression of
melanoma.
Overexpression of p53 has been found to correlate with
increased survival in patients with squamous cell carcinoma
of the tongue (Sauter et al., 1992), and may also indicate a
better prognosis in sarcoma patients (Andreassen et al.,
1992). The apparent association between elevated p53 protein
expression and a prolonged relapse-free period in our
patients with superficially spreading melanoma suggests that,
in these cases, increased levels of wild-type protein might
help restrict the proliferative capacity and thereby the degree
of malignancy of the melanoma cells. This hypothesis seems
to be supported by the finding that in three patients p53
protein immunoreactivity detected in the primary tumours
was lost in the corresponding metastases.
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